Delfi Diagnostics is a company within the Biotechnology category. Delfi Diagnostics is a biotechnology company developing high-performance, low-cost liquid biopsy tests for the early detection of cancer. The company utilizes a proprietary platform called fragmentomics, which applies machine learning to analyze patterns of DNA fragments in the bloodstream. By focusing on the structural biology of the genome rather than specific mutations, Delfi aims to make cancer screening more accessible and scalable globally.
Delfi Diagnostics was founded in 2019 and is headquartered in Baltimore, MD.
Delfi Diagnostics is rated Contender on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for Delfi Diagnostics is Strong. Significant factual deltas detected.
AI models classify Delfi Diagnostics as a Challenger. AI names competitors first.
Delfi Diagnostics appeared in 5 of 7 sampled buyer-intent queries (71%). Delfi is highly visible for technical queries related to 'fragmentomics' but faces stiff competition for broader 'liquid biopsy' and 'early cancer detection' terms from larger incumbents.
AI accurately portrays the company as a well-funded, scientifically rigorous leader in the 'fragmentomics' space. It successfully connects the brand to its Johns Hopkins roots but may struggle with the most recent clinical trial developments or specific commercial launch dates. Key gap: The specific commercial availability and FDA status of individual tests (e.g., LUNG-1) are often blurred or outdated compared to clinical trial progress.
Of 6 key facts verified about Delfi Diagnostics, 6 are well-documented (likely accurate across AI models), 0 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.
Specific pricing for clinical tests and detailed partnership terms with healthcare providers.
Buyers turn to Delfi Diagnostics for Standard Standard of Care Screening: Physicians rely on standard screening methods like colonoscopies or low-dose CT scans (LDCT) which are invasive or have lower compliance., Wait-and-See Approach: Monitoring symptoms or waiting for clinical presentations, which often results in late-stage diagnosis., Tissue Biopsy: Traditional tissue biopsies which require invasive surgical procedures to sample a tumor., among 3 documented problem areas.
Buyers evaluating Delfi Diagnostics typically ask AI models about "What is fragmentomics in cancer detection?", "liquid biopsy for lung cancer screening", "Johns Hopkins cancer detection spinoffs", and 2 similar queries.
Delfi Diagnostics's main competitors are Guardant Health. According to AI models, these are the brands most frequently named alongside Delfi Diagnostics in buyer-intent queries.
Delfi Diagnostics's core products are Delfi-LUNG (FirstGen) test, fragmentomics-based liquid biopsy platform..
Delfi Diagnostics uses Enterprise/Insurance-based clinical testing; Research collaborations..
Delfi Diagnostics serves Healthcare providers, oncology centers, health systems, and pharmaceutical researchers..
Delfi Diagnostics Unlike competitors focusing on deep sequencing of mutations, Delfi uses fragmentomics and AI to deliver high-accuracy cancer detection at a significantly lower cost and higher scalability.
Brand Authority Index (BAI) tier: Contender (exact score locked for unclaimed brands)
Archetype: Challenger
https://optimly.ai/brand/delfi-diagnostics
Last analyzed: April 10, 2026
Founded: 2019
Headquarters: Baltimore, Maryland, USA